Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
about
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerUnderstanding and altering cell tropism of vesicular stomatitis virusReplicon RNA Viral Vectors as VaccinesOncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cellsBreaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites.The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferonMurine Tumor Models for Oncolytic Rhabdo-Virotherapy.Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.Inactivated Sendai virus strain Tianjin, a novel genotype of Sendai virus, inhibits growth of murine colon carcinoma through inducing immune responses and apoptosis.Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy.Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spreadResistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activityRecent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies.Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
P2860
Q26775030-7C5D3C0F-56A4-4B7D-861E-CE75D7A7C5EAQ27021839-D75DAF81-C97D-42D6-90C8-B0722DCE1018Q27687067-6FDF62CE-F910-4779-871B-6FE7843033D9Q28076639-3C3EA846-3529-4C91-8213-EB4E00711E73Q34059067-0C384433-CF27-4F00-A230-FCEADE85D0C7Q34656877-4D9B2205-4B6E-41D4-89D7-ABC854F842D9Q35641491-B83278A6-E89B-427A-B5C7-C71CFE726F04Q35861186-297FA179-8EA9-45DB-805B-677C767210A0Q35893563-DF4FD06E-2A68-44B9-8A3F-0C15A4CBDD3AQ36202610-54CC1D7A-8499-4AB5-B93B-59BEDF9EA97AQ36667968-72E837AF-680F-4277-A64E-7667640489A2Q36682298-75AAF6EF-FCE8-48F1-8BD6-E92B30E94658Q36751597-640BDC80-DFD7-4D8D-ADBC-075F0767D5FAQ37123143-F706382C-E7EB-4DC8-9E14-7D66BE62C4AFQ37325067-6DD6C5DA-A7F6-4684-A8A4-F3B237F19EDCQ37352017-32FBDCAF-AC48-4EF4-9CBC-3E5D750A861EQ37641644-5BE54B7D-0FE9-4FF9-908C-5C7557CBD607Q37646792-2A082190-BAF7-4317-B24A-1DDC4764B90AQ38025696-AFA6D410-94F8-4789-8D36-88460AF587B6Q38221692-011B71E8-D2AD-474C-BCEF-F6179314AB37Q38676507-BE98EFB1-CF64-4D17-B0DE-9F5FC4D0FA69Q39037822-39852FF7-AFD9-42ED-B01C-125874440059Q39109430-FC5C1EAE-F975-47F4-ACF7-0F85D7A9CBEBQ39127778-B9003FC8-5DCA-4B8A-95D9-504622F6A0DAQ39224943-030A34C5-0466-46B7-A201-F3FAE5BE9657Q41770092-CDA2EB99-A3ED-466E-A8EC-4D756EC940A5Q45324769-C2407C6A-929C-4396-851C-F7D4464448CAQ50056861-BC0FE62B-298B-4C66-BEBF-BC8946363C2AQ52769266-33ED5847-9B66-4DF5-979F-B0D84CAEC1F7Q58729482-F74A49B0-B56C-45B7-A20B-72190458431E
P2860
Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Vesicular stomatitis virus as ...... creatic ductal adenocarcinoma.
@en
Vesicular stomatitis virus as ...... creatic ductal adenocarcinoma.
@nl
type
label
Vesicular stomatitis virus as ...... creatic ductal adenocarcinoma.
@en
Vesicular stomatitis virus as ...... creatic ductal adenocarcinoma.
@nl
prefLabel
Vesicular stomatitis virus as ...... creatic ductal adenocarcinoma.
@en
Vesicular stomatitis virus as ...... creatic ductal adenocarcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Vesicular stomatitis virus as ...... creatic ductal adenocarcinoma.
@en
P2093
Andrea M Murphy
Dahlia M Besmer
David A Ornelles
Megan Moerdyk-Schauwecker
Natascha Moestl
Pinku Mukherjee
Valery Z Grdzelishvili
P2860
P304
P356
10.1128/JVI.05640-11
P407
P577
2012-01-11T00:00:00Z